Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma
- Authors
- Seo Y.S.; Kim M.-S.; Yoo S.Y.; Cho C.K.; Choi C.W.; Kim J.H.; Han C.J.; Park S.C.; Lee B.H.; Kim Y.H.; Lee D.H.
- Issue Date
- 2010
- Keywords
- CyberKnife; Hepatocellular carcinoma; Stereotactic radiotherapy
- Citation
- Journal of Surgical Oncology, v.102, no.3, pp 209 - 214
- Pages
- 6
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- Journal of Surgical Oncology
- Volume
- 102
- Number
- 3
- Start Page
- 209
- End Page
- 214
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/31167
- DOI
- 10.1002/jso.21593
- ISSN
- 0022-4790
1096-9098
- Abstract
- Background and Objectives: To evaluate the toxicity and efficacy of stereotactic body radiotherapy (SBRT) for the treatment of localized hepatocellular carcinoma (HCC) in the absence of another standard treatment option. Methods: The authors reviewed the details of 38 patients with inoperable HCC (diameter < 10 cm) treated by SBRT in a prospectively registered database at their institution. All patients had been treated by transcatheter arterial chemoembolization before SBRT, which had been finally deemed ineffective. SBRT dosages (33-57Gy in three or four fractions) were administered according to tumor volumes, which ranged from 11 to 464 ml (median, 40.5 ml). Results: Two-year overall survival and local progression-free survival rates were 61.4% and 66.4%, respectively. The local response rate was 63% at 3 months after SBRT. A high radiation dose was found to be independently related to survival. A decline in liver function was observed in six patients (16%) and Grade 3 musculoskeletal toxicity in one patient (2.7%). Conclusions: This study showed that SBRT can be safely administered to select HCC patients, and these results suggest that this technique should be considered a salvage treatment. A further well-controlled large-scale study and longer follow-up are needed to determine optimal dose-fraction schedules and characterize late complications. © 2010 Wiley-Liss, Inc.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.